Jun 08, 2023 / 07:30PM GMT
Al Sandrock - Voyager Therapeutics, Inc. - President & CEO
My name is Al Sandrock, and it's my pleasure to tell you about how Voyager Therapeutics is breaking through barriers in neurology and gene therapy.
I'm going to be making some forward-looking statements. Please consult our regulatory documents. We have Voyager sit at the intersection of neurotherapeutics and gene therapy, and I believe we're in an amazing era of neurotherapeutics.
Just look at what's happened this year alone. We now have antibodies, the first disease-modifying therapies for Alzheimer's disease. We have a drug approved for the very first time in Friedreich's ataxia. We have drugs that affect that negative symptoms of schizophrenia. We've had drugs that affect the positive symptoms for (inaudible), none that affect the negative symptoms, and we see evidence of that nowadays.
We have two new medicines just this year alone approved by FDA for ALS, including tofersen, just approved for SOD1 ALS. And we have regulatory support for surrogate endpoints such as NfL for ALS.
Gene therapy is also
Voyager Therapeutics Inc at Jefferies Healthcare Conference Transcript
Mar 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers